Zealthy logo

Zealthy Review

5.5
★★★☆☆2.8/5

Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 5.5/10

Best for: not currently recommended, and listed for transparency and reader awareness only

Zealthy scores below our bar on medical oversight. Read the score breakdown before signing up.

Semaglutide

$286/mo · starting dose

Tirzepatide

$351/mo · starting dose

Price checked on Zealthy's site,

What the monthly price covers

Medication

Not stated

Provider visits

Included

Shipping

Included

Lab work

Not stated

Coaching

Included

See plans →

No insurance neededVetted by our editors

Compare top-rated alternatives ↓

Zealthy (legal entity FitRX, LLC, recently renamed to Gronk Inc.) offers compounded semaglutide and tirzepatide via an asynchronous telehealth model. Listed here for completeness with full disclosure of two FDA warning letters and active federal litigation. See the warnings and cons sections before considering it.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
CompoundedSemaglutideTirzepatide

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

Vetted alternatives to Zealthy

7.7/ 10
Partner

Ro

Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

★★★★☆3.9/5

Editorial score · methodology

$149/mosemaglutide
+ required membership
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Ro review →
8.3/ 10
Partner

Collective

Best for: the lowest flat medication price if you can absorb an annual membership fee

★★★★☆4.2/5

Editorial score · methodology

$59/mosemaglutide
+ required membership
$69/motirzepatide
+ required membership
CompoundedSemaglutideTirzepatide
Get StartedRead full Collective review →
8.3/ 10
Partner

CoreAge Rx

Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

★★★★☆4.2/5

Editorial score · methodology

$79/mosemaglutide
starting price
$129/motirzepatide
starting price
CompoundedSemaglutideTirzepatideNAD+SermorelinLegitScript Verified
Get StartedRead full CoreAge Rx review →
Zealthy logo
2.8 / 5
Our editorial rating
Visit Zealthy →

from $286/mo · no insurance needed

Zealthy at a glance

Type
GLP-1 telehealth provider
Medications
Semaglutide, Tirzepatide
Starting price
$286/mo (starting dose)
What's included
Consult · Shipping · Coaching
Availability
34 states
FDA status
2 FDA warning letters on record; see below

How we scored Zealthy

Each dimension is scored algorithmically from Zealthy'spublished pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.

Value25%

4.2/10

Zealthy's headline is $286 a month at the starting dose. Compare it with other programs on the same plan basis.

Effectiveness25%

6.8/10

Zealthy offers both semaglutide and tirzepatide, the two GLP-1 molecules with the strongest published weight-loss trial outcomes.

User Experience15%

5.8/10

Online intake and platform experience (consult included in the price); 3 platform features disclosed.

Trust & Safety15%

4.8/10

Key details fully confirmed by our editors; an FDA warning letter is on file (see the regulatory notice on this page).

Accessibility10%

6.0/10

Zealthy is available in 34 states.

Support10%

5.9/10

Coaching/dietitian access included.

6scored dimensions
679providers compared

Each checked against the provider’s own site.

Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →

How we verified this Zealthy review

Last checked November 2026
  • Confirmed current pricing across 2 dose/plan tiers
  • Confirmed availability in 34 states
  • Confirmed what the monthly price does and doesn't include
  • Checked the FDA warning-letter database for enforcement actions
  • Walked the provider's public sign-up flow, stopping before payment

Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: high.

What we checked

Provider's own pricing page
$286–$351/mo across 2 dose/plan tiers (checked November 2026)
FDA warning-letter register
An active letter is on file for this provider; see below

What to expect when you sign up with Zealthy

We walked Zealthy's public signup flow in July 2026 to document the process (the steps, pricing transparency, and what’s required) before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)

  1. 1Create an account and answer health questions (about 5 minutes).
  2. 2Select a Zealthy provider and be seen right away or schedule a visit (same-day appointments available).
  3. 3Meet with a medical provider for diagnosis and prescription if appropriate.
  4. 4If medically appropriate, the prescription is delivered to your home or picked up at a pharmacy.
Price shown only after intake
  • No specific monthly price is shown before intake; only a '$96 off Zealthy Weight Loss Program' promotion.
  • A provider visit/appointment is part of the flow, with same-day appointments available.
  • Prescription can be delivered home or picked up at a pharmacy.
  • A Subscriptions, Cancellations, and Refunds Policy is linked but terms are not shown on the funnel page.
  • Phone and email support are listed.

Zealthy customer support

GLP-1 medications Zealthy offers

Tap any medication to read our plain-English guide: how it works, dosing, side effects, and what the trials found.

Pricing

Prices re-verified

StartingCompounded
$286/mo
semaglutide

$151 medication plus a $135 monthly membership. The $151 is 'as low as … when purchased quarterly', not a month-to-month rate, and the membership is charged on top either way.

StartingCompounded
$351/mo
tirzepatide

$216 medication plus the same $135 monthly membership.

Ready to get started?

Plans and promotions change often, so check Zealthy's current pricing and active discounts before you decide.

See Zealthy pricing →

What we like

  • Serves 34 states, a meaningful nationwide footprint
  • Asynchronous model removes friction for patients who don't want a video visit
  • Independent licensed prescribers retain full clinical authority

Watch-outs

  • Two FDA warning letters for false or misleading marketing of compounded GLP-1s
  • Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
  • Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
  • Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
  • Recently rebranded to Gronk Inc. amid active enforcement
  • Kept marketing compounded semaglutide after the FDA shortage ended in Feb 2025
  • Adds a $135/month membership fee on top of medication, for a total cash price of $286–$351/month
  • Compounded only, with no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro

Our verdict: we list Zealthy as a warning, not a recommendation

This is the kind of decision where the details matter for your health and your wallet. Zealthy is the only provider on this site that we include specifically so you can see why we don't recommend it. It sells compounded semaglutide and tirzepatide through a fast, app-based telehealth funnel, and on the surface it looks like any other GLP-1 startup. Underneath, it carries two FDA warning letters, an active false-advertising lawsuit from Novo Nordisk, a federal DOJ/FTC enforcement action, and a founder whose last company settled with the FTC over similar conduct. If you read nothing else, read the trust section below before you click anything.

How Zealthy works, and the asynchronous trade-off

Zealthy runs an asynchronous model. You fill out an intake questionnaire, an independent licensed prescriber reviews it without a live video visit, and if approved your medication ships to your door. For some people that is convenient: no scheduling, no waiting room, no camera. The flip side is that there's no real-time conversation where you can ask questions, describe symptoms in your own words, or have a clinician push back. For a powerful injectable that affects appetite, blood sugar, and digestion, that lighter touch is a meaningful downside, not just a feature.

The company operates in 34 states, so coverage is reasonably broad but not nationwide. For context, the legal entity behind the brand is FitRX, LLC, which has reportedly been renamed to Gronk Inc. A corporate reshuffle in the middle of active enforcement is rarely a reassuring sign.

The pricing model: a membership fee stacked on top of the medication

The marketing and the math diverge on price. Zealthy doesn't charge one simple medication price. It charges for the medication AND layers a separate monthly membership fee on top of it. For compounded semaglutide that lands the all-in total in the upper-mid three figures per month; for tirzepatide it's higher still. Either way you're paying well above the category median of around $179 once the membership is included. The membership is not a one-time cost either. It recurs every month for as long as you stay.

How we get the market median: $179 is the middle value of each program's lowest listed ongoing monthly price for compounded semaglutide (month to month, not a first-month promo, a prepaid plan or a price with a membership on top), across the 129 programs that publish one.

  • Two separate charges: the compounded drug itself, plus a recurring monthly membership fee billed on top of it.
  • The membership is unavoidable: it's how the monthly cost climbs well past what the headline drug price implies.
  • Shipping and coaching are bundled into that membership, but you're paying a premium for them whether you use them or not.

Because the company does not publish a single clean standard rate, and because the federal complaint specifically alleges undisclosed subscription terms, you should treat any number you see in the funnel as something to confirm in writing before you hand over a card. Read exactly what recurs, how much, and how to stop it.

What you can get: compounded only, no brand names

Zealthy dispenses compounded semaglutide and compounded tirzepatide. It does not offer FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro. Compounded medications are made by a pharmacy rather than the original manufacturer, and they are not FDA-approved or independently tested for safety and effectiveness the way the brand products are. That distinction sits at the center of the legal trouble below: the FDA semaglutide shortage that once gave compounders legal room to operate ended in February 2025, and Zealthy is accused of continuing to market compounded semaglutide afterward.

The main reason to be cautious: FDA letters, lawsuits, and a familiar founder

This record is what moves Zealthy to the bottom of our list. Every claim here is sourced to a primary government or court record, not rumor:

  • FDA Warning Letter 717987 (Feb 2026) to FitRX, LLC for false or misleading marketing of compounded semaglutide and tirzepatide, including describing them as the 'active ingredient in Wegovy' and 'active ingredient in Zepbound' on products that are not FDA-approved.
  • A second, earlier FDA enforcement action in a September 2025 cease-and-desist sweep targeting telehealth marketers of compounded GLP-1s after the shortage ended.
  • An active Novo Nordisk lawsuit alleging trademark infringement and marketing compounded drugs as approved alternatives.
  • An active DOJ/FTC enforcement action alleging undisclosed subscription terms, a locked or hard-to-use cancellation process, and unauthorized sharing of health data.
  • The founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive-practice allegations.

Zealthy names no accredited compounding-pharmacy partner. With an open FDA action against it, we can't vouch for its medical oversight the way we do for vetted providers. You can read how we weigh trust, accreditation, and enforcement history in our scoring methodology.

Who should skip Zealthy (almost everyone) and the narrow case for looking closer

Skip Zealthy if you want confidence that your provider is in good standing with regulators, transparent about recurring charges, and easy to cancel. That describes the vast majority of readers. The only reason we keep it visible at all is transparency: some people will search the brand, see slick ads, and deserve to find the documented enforcement record in one place before they sign up. If you're comparison-shopping, you can get compounded semaglutide or tirzepatide from providers that don't carry two FDA warning letters and an active federal case. One of them is Trally Meds, which posts its prices before you sign up and lets you cancel in its portal, by phone or by email with no fee.

Bottom line

Zealthy is convenient and broadly available, but its problem is credibility, not convenience. Two FDA warning letters, a manufacturer lawsuit, a DOJ/FTC action over hidden subscriptions and data sharing, a mid-enforcement rebrand, and a founder with a prior FTC settlement add up to a pattern, not a coincidence. The added monthly membership also makes the true cost higher than the headline suggests. We list it for awareness and we do not recommend it. If you're set on compounded GLP-1 care, choose a provider with a clean regulatory record and pricing you can read in plain sight. One example is Remi Meds, with a named pharmacy and a full per-dose price list, though it names no medical director.

The Bottom Line

Zealthy scores below our bar on medical oversight. Read the score breakdown before signing up.

Score: 5.5/10Best for: not currently recommended, and listed for transparency and reader awareness onlyFrom: $286 a month at the starting dose

Ready to start with Zealthy?

From $286 a month at the starting dose. See current pricing and start your online intake.

Zealthy might not be your best fit if…

We rank editorially, so here’s where a different provider we track may serve you better.

  • If you want a brand-name GLP-1 such as Wegovy or Zepbound, consider altRX.
  • If you live outside its coverage area and need nationwide access, consider Ro.

Head-to-head

Compare Zealthy vs…

Zealthy scores5.5/10

Side-by-side pricing, medications and scores. Pick a matchup.

Scores are our independent editorial ratings out of 10.

Frequently Asked Questions

Zealthy is an operating telehealth company (its prescribers are independently licensed and it does dispense compounded GLP-1 medications), but our editorial team does not recommend it and lists it here for transparency only. The company (legal entity FitRX, LLC, recently renamed to Gronk Inc.) has received two FDA warning letters for marketing compounded semaglutide and tirzepatide with false or misleading claims, including representations suggesting the compounded products are equivalent to FDA-approved drugs. It also faces an active DOJ/FTC lawsuit alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing, plus a separate Novo Nordisk false-advertising lawsuit. These are serious concerns documented in primary government and court records. Review those warnings carefully and consider providers without this enforcement history before deciding.
Zealthy is an asynchronous telehealth platform offering compounded semaglutide and tirzepatide across 34 states. Its legal operating entity is FitRX, LLC, which recently rebranded to Gronk Inc. amid active federal enforcement. Prescriptions are written by independently licensed clinicians without requiring live video visits, and the platform charges a $135/month membership fee on top of the medication cost. The company was founded by Kyle Robertson, who previously founded Cerebral, a mental health platform that settled with the FTC in 2024 over deceptive practices. Zealthy is currently the subject of multiple active legal actions from the DOJ, FTC, and Novo Nordisk, which is a material risk factor for prospective patients.
Zealthy uses a two-part pricing model: a $135/month membership fee plus a separate medication charge. Compounded semaglutide runs approximately $151/month for the medication, bringing the all-in total to roughly $286/month. Compounded tirzepatide is approximately $216/month for the medication, totaling around $351/month with membership. Shipping is included. Be aware that the active DOJ/FTC enforcement specifically alleges that Zealthy's subscription terms were not clearly disclosed to customers. That is a documented billing risk to weigh before entering payment information.
Cancellation is a formally documented concern with Zealthy. The active DOJ/FTC enforcement action against the company specifically alleges "locked cancellation" and undisclosed subscription terms, meaning federal regulators have formally alleged the cancellation process is not straightforward. This goes beyond customer complaints: it is an allegation in an active federal lawsuit. If you have enrolled and wish to cancel, we recommend doing so in writing through their listed support channel and keeping a record of all correspondence. The current cancellation process cannot be confirmed from outside, and the litigation was ongoing at our last check.
Pros: Zealthy serves 34 states, uses an asynchronous model so no video visit is required, and independent licensed prescribers retain full clinical authority. Cons are significant: two FDA warning letters for misleading marketing of compounded GLP-1s; an active DOJ/FTC lawsuit alleging undisclosed billing, locked cancellation, and health-data sharing violations; an active Novo Nordisk false-advertising lawsuit; a $135/month membership stacked on top of medication cost ($286-$351/month all-in); continued marketing of compounded semaglutide after the FDA shortage ended in February 2025; and a founder with a prior FTC settlement at another company. Our overall editorial position is that readers should prioritize providers without this enforcement history until the legal matters are resolved.
Zealthy doesn't use a typed coupon code. When we last checked (June 2026), its site said: new patients get $96 off the first month, bringing it to $49 (then about $135/mo), applied automatically at signup. Confirm the current offer on Zealthy's own checkout via the link on this page; third-party "Zealthy promo code" sites are typically fake.
The main red flag is an FDA warning letter on file, which this review flags. Read it before starting. We also note: Two FDA warning letters for false or misleading marketing of compounded GLP-1s; active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives; active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Regulatory notice

Zealthy received an FDA warning letter dated September 9, 2025

The letter concerns unlawful sale of unapproved and misbranded drugs to United States consumers over the internet. FDA warning letters are public regulatory communications and do not, on their own, constitute a finding of illegal activity. Companies often respond with corrective action.

Read the full letter →

Sources

The primary regulatory filings and peer-reviewed studies cited throughout this Zealthy review:

Sources & methodology (as of November 2026)
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
  4. 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  5. 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  8. 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  9. 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  10. 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  11. 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  12. 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.

See Zealthy's current pricing

Plans from $286 a month at the starting dose. Start the online intake to check eligibility and today's price.